LabCorp ‘Wait Where You’re Comfortable’ and Mobile Check-In Options Reinforce Social Distancing Protocols
BURLINGTON, N.C.--(BUSINESS WIRE)-- LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that it is dedicating the first hour of service each day at its nearly 2,000 patient service centers (PSCs) across the U.S. for the non-COVID-19 testing needs of its most vulnerable patients. The option is aimed at making it easier for patients who are at higher risk to practice social distancing and get their critical lab testing services.
LabCorp’s first business hour of each day at PSCs will be focused on serving people who are 65 or older or who have serious underlying health conditions. LabCorp will not turn away any patient during the first business hour but encourages other patients to plan around this hour to protect vulnerable patients. Patients who believe they have been exposed to COVID-19 should not enter the patient service center. They should contact their physician or healthcare provider.
“Providing this dedicated hour each day for our most vulnerable patients can help protect those patients and help flatten the coronavirus curve,” said Adam H. Schechter, president and CEO of LabCorp. “Enhanced social distancing can limit the potential spread of the virus and offer greater peace of mind for people who have important and ongoing health and testing needs. We all have a role to play in protecting our communities, and we are committed to doing all we can to ensure the safety and health of those we serve.”
In addition to the dedicated hour for vulnerable patients, to further help reduce the risk of transmission of COVID-19 for patients visiting its PSCs, LabCorp recently launched the “Wait Where You’re Comfortable” program. Patients can check in from their mobile device or using the LabCorp Express tablet and then wait in their car or anywhere else they are comfortable. Patients receive a text message when it’s their turn to be served. To learn more about these options, visit: https://www.LabCorp.com/labs-and-appointments.
About COVID-19 Testing
LabCorp does not collect specimens for the COVID-19 test. LabCorp is playing a vital role in ramping up testing capacity for COVID-19. LabCorp made testing for COVID-19 available on Thursday, March 5, for ordering by physicians or other authorized healthcare providers anywhere in the U.S. The test detects the presence of the underlying virus that causes COVID-19 and is for use with patients who meet current guidance for evaluation of infection with COVID-19. Patients for whom testing has been ordered should not be sent to a LabCorp location to have a specimen collected. Instead, an appropriate specimen must be collected at the healthcare facility where the patient was seen and the test was ordered. The specimen should be sent to LabCorp using standard procedures. For more information on COVID-19 testing, including specific guidance on specimen collection and handling, visit: https://www.LabCorp.com/COVID-19.
About LabCorp
LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostics solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenue of more than $11.5 billion in 2019. To learn more about LabCorp, visit www.LabCorp.com, and to learn more about Covance Drug Development, visit www.Covance.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including but not limited to statements with respect to clinical laboratory testing. Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the Company’s control, including without limitation, competitive actions and other unforeseen changes and general uncertainties in the marketplace, changes in government regulations, including healthcare reform, customer purchasing decisions, including changes in payer regulations or policies, other adverse actions of governmental and third-party payers, the Company’s satisfaction of regulatory and other requirements, patient safety issues, changes in testing guidelines or recommendations, adverse results in material litigation matters, failure to maintain or develop customer relationships, our ability to develop or acquire new products and adapt to technological changes, failure in information technology, systems or data security, and employee relations. These factors, in some cases, have affected and in the future (together with other factors) could affect the Company’s ability to implement the Company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the Company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the Company’s other filings with the SEC.
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20200319005718/en/
Media: Pattie Kushner — 336-436-8263
[email protected]
Investors: Clarissa Willett — 336-436-5076
[email protected]
Source: LabCorp
